BrightSpring beats, raises guidance, sees 2026 Inflation Reduction Act revenue headwinds
BrightSpring beats Q2 2026 estimates, raises 2026 guidance, sees 2026 Inflation Reduction Act revenue headwinds of about $200 million and $175 million by segment
- Q2 2026 EPS was $0.45 and revenue was $3.9B, both ahead of analyst estimates.
- Company projected about a $200 million 2026 revenue impact in home and community pharmacy from the Inflation Reduction Act.
- BrightSpring also forecast about a $175 million 2026 revenue hit in specialty and infusion from the Inflation Reduction Act.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.